March 29, 2018 / 5:16 AM / 5 months ago

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

March 29 (Reuters) - CELYAD SA:

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

* ‍PRECLINICAL STUDY SHOWS ADDING CD28 OR 4-1BB TO CYAD-01 BRINGS NO BENEFIT FOR IN VITRO ACTIVITY OF RECEPTOR​

* TO PRESENT UPDATE FROM THINK TRIAL, NEW SHRINK AND LINK TRIALS IN METASTATIC COLORECTAL CANCER​

* ‍THINK TRIAL: PRELIMINARY EVIDENCE OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CYAD-01) CLINICAL ACTIVITY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below